TABLE 1.
ECLIPSE | ICGN |
||
---|---|---|---|
COPD Cases | Probands | Siblings | |
Subjects, n | 1,609 | 606 | 1,285 |
Age, ± SD | 63.8 (± 7.1) | 58.4 (± 5.4) | 58 (± 9.8) |
Female, % | 32.5 | 40.3 | 49.8 |
Post-bronchodilator FEV1, % predicted, ± SD | 48.1 (± 15.6) | 36.2 (± 12.9) | 77.5 (± 25.9) |
Post-bronchodilator FEV1/FVC ratio*, ± SD | 0.45 (± 0.11) | 0.37 (± 0.12) | 0.61 (± 0.15) |
Pack-years of smoking, ± SD | 50.9 (± 28) | 51.5 (± 26.7) | 40.5 (± 24.6) |
Current smoker, % | 35.5 | 33.83 | 50.82 |
Body mass index, ± SD | 26.7 (± 5.6) | 26.1 (± 6.2) | 27.2 (± 6.5) |
Fat-free body mass, ± SD†‡ | 50 (± 10.2) | ||
BODE index, ± SD†§ | 3.2 (± 2.1) | ||
Frequency of exacerbation in the past 12 mo, ± SD† | 0.83 (± 1.20) | ||
Frequency of exacerbation (2-yr follow-up), ± SD† | 2.12 (± 2.62) | ||
Quantitative emphysema, −950 HU, ± SD‖ | 18 (± 12) | 22.3 (± 14.4) | 16.08 (± 10.9) |
Radiologist score, % subjects with >5% emphysema | 66.7 | 80.8 | 39.3 |
Airway wall thickness, mm, Pi10, ± SD¶ | 3.96 (± 0.21) | 4.86 (± 0.43) | 4.78 (± 0.44) |
Definition of abbreviations: BODE = body mass index, airflow obstruction, and exercise capacity; COPD = chronic obstructive pulmonary disease; ECLIPSE = Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-point; ICGN = International COPD Genetics Network.
A total of 110 subjects from ICGN who also participated in the ECLIPSE study were eliminated from the summary of phenotypes analyzed in both ECLIPSE and ICGN cohorts.
In the ICGN, FEV1/VC was analyzed.
Phenotypes not available or analyzed in ICGN study. All 1,719 ECLIPSE subjects were included in the mean and SD estimates.
Expressed in Ω calculated using the method previously described (18).
BODE index calculated using the method previously described (17).
Percentage of lung voxels with x-ray attenuation values less than −950 HU assessed by image analysis of high-resolution computed tomography scans.
Square root of the wall area at a luminal perimeter of 10 mm.